The Unexpected Role of GCN2 Kinase Activation in Mediating Pulmonary Arterial Hypertension

Background Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and remodeling that result in right heart hypertrophy and failure. Published studies show that recessive mutations of EIF2AK4 gene (encoding GCN2, General control nonderepressibe 2 kinase) are linked to heritable pulmonary veno-occlusive disease (PVOD) in patients and EIF2AK4 mutations were also found in PAH patients although very rare. However, the role of GCN2 kinase in the pathogenesis of PAH remains unclear. Methods Eif2ak4-/- mice with genetic disruption of the kinase domain and GCN2 kinase inhibitor A-92 were employed in animal models of PH including chronic hypoxia-exposed mice and monocrotaline-challenged rats. Human lung endothelial cells (HLMVECs) were used for mechanistic studies. Endothelium-targeted nanoparticles were employed to deliver plasmid DNA to adult mice to knockout Eif2ak4 or overexpress Endothelin-1 (Edn1) selectively in ECs. Results Here we show that loss of GCN2 induced neither spontaneous PVOD nor PH in Eif2ak4-/- mice but inhibited hypoxia-induced PH evident by reduced right ventricular systolic pressure, right ventricle hypertrophy and pulmonary vascular remodeling. RNA sequencing analysis suggested Edn1 as the downstream target of GCN2. In cultured HLMVECs, GCN2 was phosphorylated and activated in response to hypoxia, mediating hypoxia-induced Edn1 expression via HIF-2α. Restored Edn1 expression in ECs in Gcn2-deficient mice reversed the reduced phenotype of hypoxia-induced PH. Furthermore, loss of endothelial Eif2ak4 in mice attenuated hypoxia-induced PH. Monocrotaline-induced PH and pulmonary vascular remodeling in rats were inhibited by GCN2 inhibitor A-92 treatment. The clinical relevance of the observation was validated by GCN2 hyperphosphorylation indicative of activation in ECs of pulmonary vascular lesions of PAH patients. Conclusion These studies demonstrate that GCN2 activation by hypoxia mediates pulmonary vascular remodeling and PAH through Edn1. Thus, targeting GCN2 signaling is a promising therapeutic strategy for treatment of PAH in patients without EIF2AK4 loss of function mutations.

[1]  G. Mutlu,et al.  Endothelial FoxM1 reactivates aging-impaired endothelial regeneration for vascular repair and resolution of inflammatory lung injury , 2023, Science Translational Medicine.

[2]  T. Shanley,et al.  Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA , 2022, Cell reports.

[3]  D. Stewart,et al.  Endothelial cells in the pathogenesis of pulmonary arterial hypertension , 2021, European Respiratory Journal.

[4]  S. Marciniak,et al.  The integrated stress response in pulmonary disease , 2020, European Respiratory Review.

[5]  G. Simonneau,et al.  The revised definition of pulmonary hypertension: exploring the impact on patient management , 2019, European heart journal supplements : journal of the European Society of Cardiology.

[6]  A. Rosenwald,et al.  A MYC–GCN2–eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer , 2019, Nature Cell Biology.

[7]  You-yang Zhao,et al.  Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension , 2018, American journal of respiratory and critical care medicine.

[8]  Fengyuan Hu,et al.  Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension , 2017, Circulation.

[9]  M. Humbert,et al.  Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  M. Humbert,et al.  Epidemiology and treatment of pulmonary arterial hypertension , 2017, Nature Reviews Cardiology.

[11]  C. Fischer,et al.  EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension , 2016, Respiratory Research.

[12]  M. Humbert,et al.  A global view of pulmonary hypertension. , 2016, The Lancet. Respiratory medicine.

[13]  M. Humbert,et al.  Initial dual oral combination therapy in pulmonary arterial hypertension , 2016, European Respiratory Journal.

[14]  Shuzhao Li,et al.  The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation , 2016, Nature.

[15]  K. Hirata,et al.  Targeted activation of endothelin-1 exacerbates hypoxia-induced pulmonary hypertension. , 2015, Biochemical and biophysical research communications.

[16]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[17]  G. Rosse,et al.  Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2. , 2014, ACS medicinal chemistry letters.

[18]  M. Humbert,et al.  EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension , 2013, Nature Genetics.

[19]  R. Benza,et al.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[20]  J. Thevelein,et al.  Pkh1 interacts with and phosphorylates components of the yeast Gcn2/eIF2α system. , 2012, Biochemical and biophysical research communications.

[21]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[22]  Ayaz Najafov,et al.  Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. , 2011, The Biochemical journal.

[23]  A. Hinnebusch,et al.  Snf1 Promotes Phosphorylation of the α Subunit of Eukaryotic Translation Initiation Factor 2 by Activating Gcn2 and Inhibiting Phosphatases Glc7 and Sit4 , 2010, Molecular and Cellular Biology.

[24]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[25]  R. Hamanaka,et al.  PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. , 2005, Molecular biology of the cell.

[26]  A. Dock-Brégeon,et al.  Faculty Opinions recommendation of Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. , 2005 .

[27]  R. Wek,et al.  Differential Activation of eIF2 Kinases in Response to Cellular Stresses in Schizosaccharomyces pombe , 2004, Genetics.

[28]  A. Gingras,et al.  Activation of GCN2 in UV-Irradiated Cells Inhibits Translation , 2002, Current Biology.

[29]  A. Hinnebusch,et al.  Mutations that bypass tRNA binding activate the intrinsically defective kinase domain in GCN2. , 2002, Genes & development.

[30]  K. Webster,et al.  Molecular Regulation of the Endothelin-1 Gene by Hypoxia , 2001, The Journal of Biological Chemistry.

[31]  A. Hinnebusch,et al.  The tRNA‐binding moiety in GCN2 contains a dimerization domain that interacts with the kinase domain and is required for tRNA binding and kinase activation , 2001, The EMBO journal.

[32]  M. Schapira,et al.  Regulated translation initiation controls stress-induced gene expression in mammalian cells. , 2000, Molecular cell.

[33]  A. Hinnebusch,et al.  Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. , 2000, Molecular cell.

[34]  J. Caro,et al.  Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: Role of hypoxia responsive element , 2000, Molecular and Cellular Biochemistry.

[35]  Ruojing Yang,et al.  Glucose Limitation Induces GCN4Translation by Activation of Gcn2 Protein Kinase , 2000, Molecular and Cellular Biology.

[36]  R. Sood,et al.  A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2alpha. , 2000, Genetics.

[37]  C. de Haro,et al.  Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase. , 1999, European journal of biochemistry.

[38]  A. Hinnebusch,et al.  Dimerization by Translation Initiation Factor 2 Kinase GCN2 Is Mediated by Interactions in the C-Terminal Ribosome-Binding Region and the Protein Kinase Domain , 1998, Molecular and Cellular Biology.

[39]  A. Hinnebusch,et al.  Autophosphorylation in the Activation Loop Is Required for Full Kinase Activity In Vivo of Human and Yeast Eukaryotic Initiation Factor 2α Kinases PKR and GCN2 , 1998, Molecular and Cellular Biology.

[40]  J. Dupuis,et al.  The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[41]  M. Koss,et al.  Pulmonary veno-occlusive disease. , 1996, Current opinion in pulmonary medicine.

[42]  R. Wek,et al.  The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids , 1995, Molecular and cellular biology.

[43]  A. Hinnebusch,et al.  Translation of the yeast transcriptional activator GCN4 is stimulated by purine limitation: implications for activation of the protein kinase GCN2 , 1993, Molecular and cellular biology.

[44]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[45]  A. Hinnebusch,et al.  Truncated protein phosphatase GLC7 restores translational activation of GCN4 expression in yeast mutants defective for the eIF-2 alpha kinase GCN2 , 1992, Molecular and cellular biology.

[46]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[47]  D. Faller,et al.  Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. , 1991, The Journal of clinical investigation.

[48]  D. Moras,et al.  Class II aminoacyl transfer RNA synthetases: crystal structure of yeast aspartyl-tRNA synthetase complexed with tRNA(Asp) , 1991, Science.

[49]  H. Hsu,et al.  Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[50]  W. Liu,et al.  Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. , 2010, Neoplasia.